Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1056/nejmoa1510665 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma |
| https://doi.org/10.1056/nejmoa1104621 | Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma |
| https://doi.org/10.1056/nejmoa1411087 | PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma |
| https://doi.org/10.1016/s1470-2045(17)30422-9 | Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study |
| https://doi.org/10.1016/s1470-2045(15)70076-8 | Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial |
| https://doi.org/10.1016/s1470-2045(17)30065-7 | Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial |
| https://doi.org/10.1016/s1470-2045(15)70122-1 | Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial |
| https://doi.org/10.1016/s1470-2045(12)70090-6 | Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial |
| https://doi.org/10.1016/s0140-6736(10)60407-2 | Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial |
| https://doi.org/10.1056/nejmoa1506027 | Belatacept and Long-Term Outcomes in Kidney Transplantation |
| https://doi.org/10.1016/j.ccell.2018.03.010 | Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas |
| https://doi.org/10.1002/hep.27726 | All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study |
| https://doi.org/10.1097/jcp.0b013e31816774f9 | The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder |
| https://doi.org/10.1093/annonc/mdq013 | Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study |
| https://doi.org/10.1001/jamaoncol.2018.5543 | Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib |
| https://doi.org/10.1002/cncr.27969 | Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab |
| https://doi.org/10.1016/0277-5379(91)90142-z | Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing |
| https://doi.org/10.1093/neuonc/noac099 | Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial |
| https://doi.org/10.2337/dc09-0517 | A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers |
| https://doi.org/10.1186/1741-7015-11-43 | Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial |
| https://doi.org/10.1002/hep.27290 | Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial |
| https://doi.org/10.1158/2326-6066.cir-16-0391 | Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape |
| https://doi.org/10.1111/j.1742-1241.2012.02911.x | Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial |
| https://doi.org/10.1093/annonc/mdf332 | Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial |
| A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. | |
| https://doi.org/10.2337/dc13-2955 | Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study |
| https://doi.org/10.1136/annrheumdis-2014-206106 | Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period |
| https://doi.org/10.1016/j.ejca.2019.05.008 | Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial |
| https://doi.org/10.1136/annrheumdis-2016-210724 | Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis |
| https://doi.org/10.1158/1078-0432.ccr-11-1991 | Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma |
| https://doi.org/10.1038/s41698-018-0051-4 | A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types |
| https://doi.org/10.1017/s1461145710000490 | Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial |
| https://doi.org/10.1192/bjp.184.6.509 | Non-adherence to antipsychotic medication regimens: Associations with resource use and costs |
| https://doi.org/10.1016/j.ejca.2019.07.001 | Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial |
| https://doi.org/10.1192/bjp.187.3.235 | Effectiveness of aripiprazole v. Haloperidol in acute bipolar mania |
| https://doi.org/10.1093/annonc/mdt161 | Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials |
| https://doi.org/10.1016/j.jad.2008.05.014 | Aripiprazole monotherapy in the treatment of acute bipolar I mania: A randomized, double-blind, placebo- and lithium-controlled study |
| https://doi.org/10.1111/j.1463-1326.2012.01659.x | Dapagliflozin monotherapy in drug‐naïve patients with diabetes: a randomized‐controlled trial of low‐dose range |
| https://doi.org/10.1185/03007995.2011.570745 | A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes |
| https://doi.org/10.1097/jgp.0b013e3181557b47 | Aripiprazole for the Treatment of Psychoses in Institutionalized Patients With Alzheimer Dementia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Assessment of Three Fixed Doses |
| https://doi.org/10.1186/s13058-020-01320-8 | Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer |
| https://doi.org/10.1111/ajt.13830 | Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study |
| https://doi.org/10.1097/01.jcp.0000178415.22309.8f | Aripiprazole for the Treatment of Psychosis in Patients With Alzheimer's Disease |
| https://doi.org/10.1007/s00213-006-0564-3 | Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine |
| https://doi.org/10.1158/1535-7163.mct-19-1020 | A Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma |
| https://doi.org/10.1038/s42255-020-00316-0 | The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer |
| https://doi.org/10.1111/bjh.14787 | Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: |
| Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. | |
| https://doi.org/10.1158/2326-6066.cir-20-0586 | Hallmarks of Resistance to Immune-Checkpoint Inhibitors |
| https://doi.org/10.1136/annrheumdis-2020-218599 | Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial |
| https://doi.org/10.3109/08037051.2015.1116258 | Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin–angiotensin system blockade |
| https://doi.org/10.1097/jgp.0b013e318165db77 | A Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole for the Treatment of Psychosis in Nursing Home Patients with Alzheimer Disease |
| https://doi.org/10.1161/circulationaha.119.044584 | Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial |
| https://doi.org/10.1192/bjp.bp.108.049965 | Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study |
| https://doi.org/10.1111/jvh.12465 | Memory re‐differentiation and reduced lymphocyte activation in chronic |
| https://doi.org/10.1016/s1470-2045(17)30015-3 | Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial |
| https://doi.org/10.1136/annrheumdis-2015-207709 | Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study |
| https://doi.org/10.1158/1078-0432.ccr-16-2842 | Nivolumab Exposure–Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non–Small Cell Lung Cancer |
| https://doi.org/10.1158/0008-5472.can-20-2066 | Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity |
| https://doi.org/10.1038/s41467-019-11493-2 | Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells |
| https://doi.org/10.1016/j.trci.2018.10.007 | A randomized, single ascending dose study of intravenous BIIB092 in healthy participants |
| https://doi.org/10.1186/1471-244x-8-95 | The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913) |
| https://doi.org/10.1002/acr.20283 | Abatacept improves health‐related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis |
| https://doi.org/10.1161/circulationaha.119.045323 | Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure |
| https://doi.org/10.1002/art.40659 | Salivary Gland Stem Cells Age Prematurely in Primary Sjögren's Syndrome |
| https://doi.org/10.1200/jco.2014.32.18_suppl.lba9008 | Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial. |
| https://doi.org/10.3111/13696998.2014.923891 | Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin |
| https://doi.org/10.1002/art.40466 | Subcutaneous Abatacept in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis |
| https://doi.org/10.1016/s2665-9913(21)00122-3 | Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure |
| https://doi.org/10.1111/1753-0407.12357 | Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial |
| https://doi.org/10.1016/j.jchromb.2011.08.025 | Full-scan high resolution accurate mass spectrometry (HRMS) in regulated bioanalysis: LC–HRMS for the quantitation of prednisone and prednisolone in human plasma |
| https://doi.org/10.1200/jco.2018.36.4_suppl.553 | Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142. |
| https://doi.org/10.1093/noajnl/vdac025 | Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143 |
| https://doi.org/10.1111/j.1468-1293.2011.00927.x | Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women |
| https://doi.org/10.1200/jco.2020.38.4_suppl.11 | Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update. |
| https://doi.org/10.55563/clinexprheumatol/h9tc57 | Rheumatoid arthritis-associated interstitial lung disease: epidemiology, risk/prognostic factors, and treatment landscape |
| https://doi.org/10.1053/j.gastro.2014.10.007 | Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection |
| https://doi.org/10.1093/cid/ciw163 | 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens |
| https://doi.org/10.1016/j.jval.2021.03.009 | Mapping EQ-5D-3L to EQ-5D-5L |
| https://doi.org/10.1158/1078-0432.ccr-22-0591 | Report of the First International Symposium on NUT Carcinoma |
| https://doi.org/10.1185/03007991003779380 | Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study |
| https://doi.org/10.1136/annrheumdis-2011-200355 | Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study |
| https://doi.org/10.1186/s13075-021-02607-7 | HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA |
| https://doi.org/10.1002/sim.9337 | TITE‐BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late‐onset toxicity and efficacy |
| https://doi.org/10.1002/cncr.34366 | Clinical activity of |
| https://doi.org/10.1200/jco.2020.38.15_suppl.4040 | Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update. |
| https://doi.org/10.1002/cam4.5434 | Biomarkers predictive of response to pembrolizumab in head and neck cancer |
| https://doi.org/10.1161/circheartfailure.120.007351 | In Vitro and In Vivo Evaluation of a Small-Molecule APJ (Apelin Receptor) Agonist, BMS-986224, as a Potential Treatment for Heart Failure |
| https://doi.org/10.3851/imp1666 | Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen |
| https://doi.org/10.1200/jco.2012.30.15_suppl.6506 | Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib. |
| https://doi.org/10.2147/ceor.s223760 | <p>Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe</p> |
| https://doi.org/10.1200/jco.2012.30.15_suppl.6504 | Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up. |
| https://doi.org/10.4155/bio.15.80 | An Integrated Multiplatform Bioanalytical Strategy for Antibody–Drug Conjugates: A Novel Case Study |
| https://doi.org/10.1136/jitc-2021-003743 | Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 |
| https://doi.org/10.1200/op.21.00883 | National Survey on the Effect of Oncology Drug Shortages in Clinical Practice: A Hematology Oncology Pharmacy Association Survey |
| https://doi.org/10.1111/jgh.13379 | A phase 3, open‐label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin |
| https://doi.org/10.2217/fon-2019-0025 | I-O Optimise: A Novel Multinational Real-World Research Platform In Thoracic Malignancies |
| https://doi.org/10.1002/cpt.1724 | A Machine‐Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma |
| https://doi.org/10.1182/blood.v126.23.28.28 | Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up |
| https://doi.org/10.1161/circoutcomes.121.008005 | Anticoagulation Treatment and Outcomes of Venous Thromboembolism by Weight and Body Mass Index: Insights From the Veterans Health Administration |